Laia Paré

10PUBLICATIONS
85CO-AUTHORS
Predictive and prognostic markersEnvironmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Dec 01, 2025
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera

|Jan 17, 2025
Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.

Maria Vidal, Claudette Falato, Tomás Pascual

|Jul 12, 2024
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.

Antonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany

|Mar 06, 2024
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.

Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal

|Sep 07, 2023
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.

Maria Vittoria Dieci, PierFranco Conte, Giancarlo Bisagni

|Apr 29, 2023
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.

Francesco Schettini, Nuria Chic, Fara Brasó-Maristany

Pageof 2

Frequent Collaborators

9 joint publications

Aleix Prat

4 joint publications

Tomás Pascual

4 joint publications

Fara Brasó-Maristany

3 joint publications

Maria Vidal